SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

Appointment of the Interim CEO to the SBTX Board of Directors

9 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has confirmed the appointment of Rachel Parsonage, Interim CEO to the Board of Directors. Her appointment was subject to normal regulatory due diligence carried out by the Company's Nominated Adviser, which is now complete.

Martin Hunt, Executive Chairman of SkinBioTherapeutics, said:

"Rachel has been in the post of Interim CEO for just a week so far, and already, she has met the majority of the team and is getting under the skin of the business, including building relationships with our key partners. Her deep experience in leading consumer beauty and wellness companies is evident in her approach, and she has a clear plan of what she wants to achieve in the immediate near term. In the meantime, we are waiting for the outcome of the external investigation as well as preparing for the HY results. We will make further announcements on these events in due course." 

-Ends-

The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

Thumbnail image

Interim CEO, Rachel Parsonage

For more information please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix^®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix^® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

Background of Rachel Parsonage

Rachel is a seasoned senior executive with over 25 years' experience leading consumer beauty and wellness businesses through growth and change. She has held CEO and transformational level leadership roles across owned and licensed brand portfolios in both domestic and international markets. She has been involved in financial and business model management, operations and inventory management, and the strengthening of corporate governance. Rachel has also worked closely with boards, founders, lenders and partners to navigate periods of transition.

Currently, Rachel runs her own advisory consultancy, Alera Advisory. Before then, she was at KMI Brands for over 16 years, rising from Managing Director to Chief Executive, where she scaled and stabilised a portfolio of owned and licensed beauty brands. Before then, Rachel was Managing Director at This Works, a premium British aromatherapy and skincare brand with UK and US focus, and previously, she was owner of Vita Management, an independent consultancy. Prior to this, she was General Manager at Pacific Direct, a global hotel manufacturing amenity company providing brand development for hotels working with luxury brands, Elemis, Penhaligons and White Company. Rachel is an alumnus of the Business Growth Programme (BGP), part of Cranfield's Executive Development Programme.